Background: Although some β-blockers are effective for patients after acute myocardial infarction (AMI), few studies have compared their additive effects on renin-angiotensin system inhibitors (RAS-Is).
cute myocardial infarction (AMI) can be fatal, 1,2 but early treatment with a renin-angiotensin system inhibitor (RAS-I), such as an angiotensin-convertingenzyme inhibitor (ACE-I) or angiotensin-II receptor blocker (ARB), has been established as the primary therapy to improve cardiac function and outcome in patients after AMI. 3, 4 It has also been reported that early treatment with β-blockers reduces mortality rates and ischemic events in patients after AMI. 5, 6 Among the β-blockers, carvedilol is a non-selective β-adrenergic receptor blocker that also induces α1-adrenergic receptor blockade and has been shown to improve the clinical status of AMI patients. 6, 7 In contrast, bisoprolol is a highly selective β1-adrenergic receptor blocker that has also been shown to be effective for AMI patients. 8, 9 Although these β-blockers are effective agents for improving the prognosis of AMI patients, few reports have compared their additive effects in AMI patients who have previously received early RAS-Is treatment. Furthermore, it might be difficult to use both RAS-Is and β-blockers to treat AMI patients with unstable conditions after admission. Therefore, this study was designed to investigate the additive effects of these β-blockers on RAS-Is in patients after AMI. In addition, we compared the effects of carvedilol and bisoprolol.
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Study Population
This study is based on data collected over a 60-month period (September 1, 2004 to September 1, 2009) from 382 consecutive AMI patients who were admitted to our hospital ( Figure 1 ). Of these 382 patients, 340 were treated by primary coronary revascularization, such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Patients were excluded from the study if they had been treated without undergoing primary coronary revascu-Additive Effects of β-Blockers After AMI larization (n=42 [deaths, n=18]), if they had already been taking any β-blockers or RAS-Is before admission (n=41 [deaths, n=5]), if they had been treated without starting any RAS-Is (ARBs if ACE-Is were not acceptable) immediately after admission (n=33 [deaths, n=12]), or if they had endstage renal disease requiring dialysis therapy (n=15 [deaths, n=3] ). Finally, of the 340 patients, 251 were enrolled in this study.
This study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Tokyo Medical and Dental University.
Procedures
The study was a retrospective, non-randomized, single-center trial. The patients enrolled in the study were divided into 2 groups according to the agents administered after admission: the first group was treated without any β-blockers (no-β-blocker group, n=80) and the second group was administered β-blockers before discharge (β-blocker group, n=171; carvedilol [n=91] or bisoprolol [n=80]). Because there is no recommendation of which β-blocker should be used for AMI patients in the present guidelines and because medical insurance does not permit the use of bisoprolol for heart failure patients, the choice of agent was left to the discretion of the attending physician. After discharge, the patients continued treatment with either carvedilol or bisoprolol, with the dose being carefully increased to tolerance. The diagnosis of AMI was made on the basis of chest pain persisting for at least 30 min, ST segment elevation of 0.1 mV in at least 2 contiguous ECG leads, and elevation of serum creatine kinase-MB isoenzyme levels to more than twice the upper limit of the normal range in accordance with the criteria indicated in the American Heart Association (AHA)/American College of Cardiology (ACC) guidelines. 1,2 Furthermore, patients in each group were divided into 2 subgroups according to risk: a low prognostic risk subgroup (low-risk subgroup) and a high prognostic risk subgroup (high-risk subgroup). In the low-risk subgroup, patients fulfilled all of the following criteria: left ventricular (LV) ejection fraction (LVEF) ≥40%, successful reperfusion, and the absence of significant ventricular arrhythmias. Patients who did not fulfill the criteria were classified as high risk. The diagnosis of acute heart failure (AHF) was made on the basis of the criteria recommended in the Framingham Heart Study. The following assessments were performed: clinical symptom evaluation, physical examination, venous blood sample analyses, chest radiography, electrocardiography, and echocardiography. During each echocardiographic study, LV diastolic dimension (LVDd), LV systolic dimension (LVDs), interventricular septum thickness (IVST), posterior wall thickness (PWT), and left atrial dimension (LAD) were measured using the M-mode in the parasternal long-axis view by the leading edge-to-edge conventional methods. LVEF was calculated by Teichholtz's method or by modified Simpson's method when LV dilatation or regional decrease of LV wall motion occurred. The deceleration time of the mitral inflow E-wave (DT) and the ratio of the velocities of the mitral inflow E-wave to the A-wave (E/A ratio) were measured as markers of diastolic function. Clinical data were obtained just prior to discharge when the hemodynamic condition of the patient had stabilized. After 12 months of treatment, these parameters were re-measured and compared with the initial data. The survival rate was defined as the proportion of patients who did not die of any cause within 12 months of discharge, whereas the car- HL, hyperlipidemia; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; IHD, ischemic heart disease; ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-II receptor blocker; CCB, calcium-channel blocker; PDEI, phosphodiesterase-III inhibitor. Additive Effects of β-Blockers After AMI diac event-free rate was defined as the proportion of patients who had no major adverse cardiovascular events, such as acute coronary syndrome or AHF.
Statistical Analyses
All values are expressed as mean (standard deviation), whereas categorical variable data are expressed as the number and percentage of patients. Fisher's exact test or the chi-square test was used to compare categorical variables, whereas survival and cardiac event-free rates were analyzed by the log-rank test. Survival and cardiac event-free curves were calculated using Kaplan -Meier estimates. The measured parameters were compared by means of analysis of variance for multiple comparisons to avoid false-positive results. If changes were significant, a parametric or non-parametric test was performed (SPSS software; SPSS Chicago, IL, USA). Pearson's or Spearman's correlation analysis was used to assess the association between the measured parameters. Differences were considered significant at P<0.05.
Results
Clinical Characteristics
There were no significant differences between the 2 groups in terms of age, sex, Killip's classification, location of the culprit lesion, method of primary revascularization, or prevalence of hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, chronic obstructive pulmonary disease, heart failure, ischemic heart disease (IHD), smoking, or medical history of IHD at the time of admission (Table 1 ). There were also no significant differences between the 2 groups in terms of Thrombolysis In Myocardial Infarction (TIMI) classification before and after PCI, the onset-to-door and doorto-balloon times, presence of Q-waves and ST-resolutions, or usage of drug-eluting stents (data not shown). Regarding cardiac medications, the administration of RAS-Is, statins, calcium channel blockers (CCBs), diuretics, nitrates, amiodarone, aspirin, ticlopidine, clopidogrel, and warfarin was similar in the 2 groups. In addition, the 2 groups had similar usage of RAS-Is ( Table 2 ). The dose of RAS-Is used for patients in the no-β-blocker group was 2-fold higher than that in the β-blocker group (Table 2 ). Many patients in the β-blocker group were treated with lower doses of RAS-Is, compared with the common doses, instead of with β-blockers. Furthermore, of the 80 patients in the no-β-blocker group, 47 were categorized as the low-risk subgroup, and 33 were classified as the high-risk subgroup. Of the 171 patients in the β-blockers group, 103 were categorized as the low-risk subgroup, and 68 were classified as the high-risk subgroup.
In each risk subgroup, clinical characteristics did not significantly differ between the no-β-blocker and β-blocker groups. Regarding the choice of β-blocker, clinical characteristics did not significantly differ between the carvedilol and bisoprolol groups (data not shown). 
After 12 months
Hemodynamics and Blood Analyses
Systolic blood pressure (BP), diastolic BP, heart rate (HR), and QRS-complex duration (QRSd) were similar in the 2 groups at baseline (Table 3 ). There were also no differences between the 2 groups regarding cardiac function analyzed with echocardiographic measurements (LVEF, IVST, PWT, LAD, DT, and E/A ratio); cardiothoracic ratio on chest radiographs or the levels of brain natriuretic peptide (BNP), metalloproteinase (MMP)-2, MMP-9, C-reactive protein (CRP), creatinine, hemoglobin, blood urea nitrogen, agebased estimated glomerular filtration rate (eGFR), albumin, creatine kinase, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol, or hemoglobin-A1c. In each risk subgroup, hemodynamic and blood analysis data did not significantly differ between the no-β-blocker and β-blocker groups. Regarding the choice of β-blocker, the results did not significantly differ between the carvedilol and bisoprolol groups (data not shown). After 12 months of treatment, systolic BP, diastolic BP, LVEF, and CRP significantly decreased compared with baseline values in the 2 groups. In contrast, although HR, BNP, and MMP-9 significantly decreased compared with baseline values in the β-blocker group, those in the no-β-blocker group did not significantly change. Additionally, eGFR did not significantly change in either group. The percent changes in systolic and diastolic BP were not significantly different between the 2 groups. However, the improvement in HR, LVEF, and levels of BNP, MMP-2, and MMP-9 was greater in the β-blocker group than in the no-β-blocker group (Table 4) . Regarding the 2 risk subgroups, the results exhibited similar tendencies between the no-β-blocker and β-blocker groups. The changes in MMP-2 and MMP-9 levels were significantly correlated with the LVEF and BNP levels but not with LVDd, LVDs, eGFR or CRP levels in both the no-β-blocker and β-blocker groups with either low-or high-risk classification (Table 5) . Furthermore, regarding the 2 β-blockers, although the percentage changes in systolic BP, diastolic BP, and HR were not significantly different between the 2 β-blocker groups, carvedilol induced greater improvement in LVEF and the BNP, MMP-2, and MMP-9 levels than bisoprolol Peak CK is expressed as the highest level of CK after admission. BP, blood pressure; HR, heart rate; QRSd, QRS-wave complex duration; LVEF, left ventricular ejection fraction; LVDd, left ventricular enddiastolic diameter; LVDs, left ventricular end-systolic diameter; IVST, interventricular septal thickness; PWT, posterior wall thickness; E/A ratio, a smaller ratio of the mitral inflow E-wave to A-wave; DT, deceleration time of the mitral inflow E-wave; LAD, left atrial diameter; CTR, cardiothoracic ratio; BNP, brain natriuretic peptide; CRP, C-reactive protein; Cre, creatinine; BUN, blood urea nitrogen; eGFR, age-based estimated glomerular filtration rate; UA, uric acid; Alb, albumin; Hb, hemoglobin concentration; CK, creatine kinase; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin-A1c; MMP, metalloproteinase. Additive Effects of β-Blockers After AMI (Table S1 ).
In addition, although we analyzed blood samples extracted from each coronary artery distal to the culprit lesion, MMP-2 and MMP-9 levels did not significantly differ from the data for venous blood samples.
Dose of β-Blocker
In the carvedilol group, patients were first administered a dose of 3.48±1.61 mg/day. After 12 months of treatment, the mean dose of carvedilol was 7.71±4.58 mg/day. In the bisoprolol group, patients were first administered a dose of 1.26± 0.57 mg/day; after 12 months, the mean dose had increased to 2.47±1.20 mg/day. The doses of both β-blockers were nearly doubled.
Clinical Outcome
Evaluation of the causes of death revealed that in the no-β-blocker group, 4 patients died of AMI, 2 of sudden cardiac death, and 5 of AHF, whereas in the β-blocker group, 3 patients died of AMI and 4 of AHF (Table 6 ). Although the percentages of AMI and AHF did not significantly differ between the 2 treatment groups, the total number of deaths and sudden cardiac deaths significantly decreased in the β-blocker group compared with the no-β-blocker group. Evaluation of cardiac events revealed that in the no-β-blocker group, 2 patients had AMI, 6 had unstable angina pectoris (UAP), 19 had AHF, and 2 had ventricular tachycardia, whereas in the β-blocker group, 2 patients had AMI, 4 had UAP, 19 had AHF, and 2 had vasospastic angina (VSA). Although the percentages of AMI, UAP, VSA, and stroke did not significantly differ between the 2 treatment groups, the total number of cardiac events and the percentages of AHF and ventricular tachycardia significantly decreased in the β-blocker group compared with the no-β-blocker group. Regarding the 2 risk subgroups, in both the no-β-blocker and β-blocker groups the percentages of deaths and cardiac events in the high-risk subgroup were higher than those in the low-risk subgroup.
Regarding the choice of β-blocker, the causes of death did not significantly differ between the 2 groups. Evaluation of cardiac events revealed that in the carvedilol group, 1 patient had AMI, 2 had UAP, 6 had AHF, and 1 had VSA, whereas in the bisoprolol group, 1 patient had AMI, 2 had UAP, 13 had AHF, and 1 had VSA (Table S2 ). Although the percentage of AHF significantly decreased in the carvedilol group compared with the bisoprolol group, other parameters did not significantly differ between the 2 groups.
The survival (86% vs. 96%; P=0.006) and cardiac eventfree rates (64% vs. 84%; P=0.0003) were lower in the no-β-blocker group than in the β-blocker group (Figure 2) . Regarding the low-risk classification, the survival (91% vs. 98%; P=0.06) and cardiac event-free rates (81% vs. 92%; P=0.04) were lower in the no-β-blocker group than in the β-blocker group. Regarding the high-risk classification, the survival (79% vs. 93%; P=0.04) and cardiac event-free rates (39% vs. 72%; P=0.002) were also lower in the no-β-blocker group than in the β-blocker group. In addition, these rates did not Tables 1,3 . Additive Effects of β-Blockers After AMI significantly differ between the carvedilol and bisoprolol groups ( Figure S1 ).
Discussion
In the present study, the characteristics of the 2 treatment groups before the study did not differ; therefore, the effectiveness of the β-blockers was clearly comparable. The doses of RAS-Is used for patients who were treated without β-blockers were at least double the doses for patients who were treated with β-blockers throughout the entire study period. This result suggests that the required good BP control increased the dose of RAS-Is in patients not receiving β-blocker treatment compared with those receiving β-blocker treatment. In the AHA/ACC guidelines, it is recommended to treat patients after AMI with ACE-Is or β-blockers until a target BP <140/ 90 mmHg is reached (<130/80 mmHg for those with diabetes or chronic kidney disease). Furthermore, it is also recommended that a target BP goal of 120/80 mmHg for post ST-elevation MI may be reasonable. In the 2 treatment groups after 12-months, BP reduced to below the target levels. As it has been controversial whether the immediate addition of β-blockers after AMI or increased dose of RAS-Is preferentially without β-blockers is better for patients, especially among low-risk patients, 10 the physicians in this study at first chose the immediate addition of β-blockers; however, small doses of RAS-Is were administered to the patients. In contrast, when the physicians could not add β-blocker therapy, either because patients refused to take new agents or there was a concern that patients would experience side effects of β-blocker therapy such as severe bradycardia, Raynaud syndrome, orthostatic hypotension, VSA, or chronic obstructive pulmonary disease, these patients were preferentially given higher doses of RAS-Is without β-blockers based on previous studies that have shown that adequately increased doses of RAS-Is improve cardiac function in patients with AMI. 11 Although the baseline data did not differ between the 2 treatment groups, the discretion of the attending physician might have affected the different outcomes after treatment. Our findings show that the former therapy is more beneficial for AMI patients with regard to improved survival and cardiac eventfree rates, LVEF, HR, and blood markers of cardiac function. The MMP family of endopeptidases acts as physiologic regulators of the extracellular matrix. Altered activity of the gelatinases, particularly MMP-9, has been implicated in the structural changes occurring after experimental AMI, 12 and intracellular MMP-2 may be causal to acute myocardial dysfunction after ischemia -reperfusion injury. 13 Furthermore, it has been reported that elevated MMP-2 and MMP-9 levels are associated with the development of cardiac dysfunction after AMI in humans. 14, 15 In our study, although the changes in MMP-2 and MMP-9 levels were significantly associated with LVEF and BNP in both the no-β-blocker and β-blocker groups, the decreases in the MMP-2 and MMP-9 levels in the β-blocker group were significantly larger than those in the no-β-blocker group. These results suggest that the combi- Figure 2 . Kaplan - Meier curves of (a) survival and (b) cardiac event-free rates in patients in the 2 treatment groups and (c) survival and (d) cardiac event-free rates in patients between the 2 risk subgroups. Note: time is expressed in days. P value refers to the log-rank analysis. KONISHI M et al.
nation of RAS-Is and β-blockers is cardioprotective by suppressing MMP-2 and MMP-9 levels, which are presumably related to LV remodeling. Previous studies have shown that stimulation of β1-adrenergic receptors induces the inotropic and chronotropic effects of norepinephrine, 16 and cardiac ischemia and arrhythmia have been induced by exerciseinduced tachyarrhythmia caused by norepinephrine release from sympathetic nerve endings. 17 The former therapy should affect β1-adrenergic receptors, decrease HR, and prevent cardiac events after AMI. Furthermore, eGFR changes did not differ between the 2 groups, although many studies have shown that adequately increased doses of RAS-Is improve renal function in patients with cardiac diseases. 18, 19 Conversely, it has been shown that carvedilol might be preferable for preventing the development of chronic kidney disease. 20 These results are attributable not only to β-blockers but also the other drugs such as diuretics, CCBs, nitrates, and antiplatelet agents taken by many of the patients prior to the start of our study.
Regarding risk classification, clinical outcomes were similar between the no-β-blocker and β-blocker groups. That result suggests that β-blocker therapy in addition to RAS-I therapy in AMI patients is more effective than treatment without β-blockers for both low-and high-risk patients, although β-blocker therapy is recommended as a class I treatment in high-risk patients and as a class IIa treatment in low-risk patients in the AHA/ACC guidelines.
Regarding the 2 β-blockers, we compared carvedilol, a typical non-selective β-adrenergic and α1-adrenergic receptor blocker, with bisoprolol, a typical highly selective β1-adrenergic receptor blocker because the question of which β-blocker is better for AMI patients remains controversial. 6, 8 Our results indicated that carvedilol induced greater improvement in LVEF and the levels of BNP, MMP-2, and MMP-9, and more effectively prevented cardiac event and death than bisoprolol, although the survival and cardiac eventfree rates did not significantly differ between the 2 β-blocker groups. BNP is the major hormone for assessing cardiac function, because it is known to decrease when cardiac function improves. 2 Our results support the usefulness of carvedilol in the treatment of AMI compared with bisoprolol. It has been shown that MMP-2 and MMP-9 are specific agents that deteriorate cardiac function after AMI. 21 In addition, it has been reported that carvedilol inhibits MMP-2 and MMP-9 by dually blocking β-adrenergic and α1-adrenergic receptors in experimental models. 22 Moreover, carvedilol has been shown to exhibit antioxidant properties in various animal models. 23, 24 These effects should be associated with the cardioprotection of carvedilol observed in our study. Further studies are required to investigate the molecular and electrophysiological mechanisms of these beneficial actions.
In contrast, the doses of the 2 β-blockers in our study were lower than the common doses found in many large-scale trials. However, several trials including Japanese patients with HF indicated that BP and HR decreased adequately with the use of low doses of carvedilol and bisoprolol. [25] [26] [27] In addition, the dose of carvedilol is considered important for the management of cardiac sympathetic nerve activity. 28 These differences in the doses used by Japanese patients and patients of other nationalities may be related to the pharmacological heterogeneity of β-blockers. Our results suggested that low doses of these agents could also influence cardioprotection after AMI, although further investigation of the doses is required.
Moreover, a few patients using β-blockers had VSA. It has been reported that β-blockers often induce coronary artery vasospasm, 29 and thus, more careful management of VSA might be necessary when additive β-blocker therapy is used.
Study Limitations
This study was performed retrospectively. Patients were selected for the 2 groups at the physician's discretion. We could not exclude the possibility that the addition and selection of the 2 β-blockers were made on the basis of the clinical status of patients. Although no significant differences were observed between the 2 groups in the baseline characteristics of the patients, other indicators should be evaluated to assess cardiac function improvement after AMI. In particular, levels of atrial natriuretic peptide, N-terminal pro-BNP, and other cytokines associated with cardiac function should be assessed.
Conclusion
Our study demonstrates that among AMI patients β-blocker therapy in addition to RAS-I therapy is more effective than treatment without β-blockers. Furthermore, carvedilol produced more favorable outcomes for AMI patients than bisoprolol in regard to worsening of HF. However, further studies with longer duration and larger numbers of AMI patients are needed to determine whether there are any differences between the effects of the 2 β-blockers on AMI improvement.
